Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zeta Global Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – ZETA
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Zeta Global Holdings Corp. (“Zeta” or the “Company”) (NYSE: ZETA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-58
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TMC the metals company Inc. of Class Action Lawsuit and Upcoming Deadlines – TMC
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against TMC the metals company Inc. (“TMC” or the “Company”) (NASDAQ: TMC) and certain officers. The class action, filed in the United States District Court for th
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Visa Inc. of Class Action Lawsuit and Upcoming Deadlines – V
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Visa Inc. (“Visa” or the “Company”) (NYSE: V). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming Deadlines – HUMA
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Xerox Holdings Corporation of Class Action Lawsuit and Upcoming Deadlines – XRX
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ASP Isotopes Inc. of Class Action Lawsuit and Upcoming Deadlines – ASPI
NEW YORK, Dec. 9, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against ASP Isotopes Inc. (“ASPI” or the “Company”) (NASDAQ: ASPI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-99
Redbrick Connect 2024 Wraps Up Successfully Advancing the Digital Creative Ecosystem
SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ — The global creator festival Redbrick Connect 2024, hosted by the cloud-based game creation platform Redbrick, concluded successfully on November 30 at COEX in Samseong-dong. The event showcased creative and innovative game projects, earning enth
GOL to File Proposed Chapter 11 Plan of Reorganization and Related Disclosure Statement with the U.S. Bankruptcy Court
Filing Permits the Company to Stay on Track for Timely Completion of Restructuring Process SÃO PAULO, Dec. 9, 2024 /PRNewswire/ — GOL Linhas Aéreas Inteligentes S.A. (the “Company” or “GOL”) (B3: GOLL4), one of the leading airlines in Brazil, and Abra Group Limited (
Agoda releases generative AI film to capture the joy of travel
The second in a series of creative AI projects, Leo’s Christmas Adventures is designed to inspire a new generation of tech talent SINGAPORE, Dec. 10, 2024 /PRNewswire/ — Ahead of the Holiday season, digital travel platform Agoda has released a new short film, ‘Leo’s Magical
IASO Bio Presented Study Findings on the Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma with Equecabtagene Autoleucel(FUCASO) Myeloma at 2024 ASH
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 9, 2024 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today shared findings
